Tohoku University Tohoku Medical Megabank Organization (Eiichi N. Kodama)
2022.05.17

1.   Sugawara Junichi, Ishikuro Mami, Obara Taku, et al. Maternal Baseline Characteristics and Perinatal Outcomes: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study. Journal of Epidemiology. 2022; 32 (2): JE20200338. doi:10.2188/jea.JE20200338  
2.   Fuse Nobuo, Sakurai Miyuki, Motoike Ikuko N., et al. Genome-wide Association Study of Axial Length in Population-based Cohorts in Japan. Ophthalmology Science. 2022; 2 (1): 100113. doi:10.1016/j.xops.2022.100113  
3.   Yamada Mitsuhiro, Motoike Ikuko N., Kojima Kaname, et al. Genetic loci for lung function in Japanese adults with adjustment for exhaled nitric oxide levels as airway inflammation indicator. Communications Biology. 2021; 4 (1): 1288. doi:10.1038/s42003-021-02813-8  
4.   Takase Masato, Nakamura Tomohiro, Hirata Takumi, et al. Association between fat mass index, fat‐free mass index and hemoglobin A1c in a Japanese population: The Tohoku Medical Megabank Community‐based Cohort Study. Journal of Diabetes Investigation. 2021; : . doi:10.1111/jdi.13729  
5.   Hozawa Atsushi, Tanno Kozo, Nakaya Naoki, et al. Study profile of the tohoku medical megabank community-based cohort study. Journal of Epidemiology. 2021; 31 (1): 65-76. doi:10.2188/jea.JE20190271  
6.   Hattori Shin-ichiro, Higashi-Kuwata Nobuyo, Hayashi Hironori, et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications. 2021; 12 (1): 668. doi:10.1038/s41467-021-20900-6  
7.   Oe Chihiro, Hayashi Hironori, Hirata Kazushige, et al. Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related Proteins. ACS Infectious Diseases. 2020; 6 (6): 1490-1500. doi:10.1021/acsinfecdis.9b00305  
8.   Saito Sho, Hayakawa Kayoko, Tsuzuki Shinya, et al. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan. Antimicrobial Agents and Chemotherapy. 2020; 65 (3): 251-257. doi:10.1128/AAC.01483-20  
9.   Nakagawara Kohsuke, Hayashi Hironori, Kawaji Kumi, et al. Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. Antiviral Chemistry and Chemotherapy. 2020; 28 : 204020662092131. doi:10.1177/2040206620921319  
10.   Kuriyama Shinichi, Metoki Hirohito, Kikuya Masahiro, et al. Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study): rationale, progress and perspective. International Journal of Epidemiology. 2020; 49 (1): 18-19m. doi:10.1093/ije/dyz169  
11.   Tsukada Kento, Shinki Shono, Kaneko Akiho, et al. Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. Nature Communications. 2020; 11 (1): 1830. doi:10.1038/s41467-020-15664-4  
12.   Oikawa Yoshitsugu, Izumi Rumiko, Koide Masashi, et al. Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PLOS ONE. 2020; 15 (12): e0231064. doi:10.1371/journal.pone.0231064  
13.   Tsuboi Akito, Matsui Hiroyuki, Shiraishi Naru, et al. Design and Progress of Oral Health Examinations in the Tohoku Medical Megabank Project. The Tohoku Journal of Experimental Medicine. 2020; 251 (2): 97-115. doi:10.1620/tjem.251.97  
14.   Siarot Lowela, Chutiwitoonchai Nopporn, Sato Hirotaka, et al. Identification of human immunodeficiency virus type-1 Gag-TSG101 interaction inhibitors by high-throughput screening. Biochemical and Biophysical Research Communications. 2018; 503 (4): 2970-2976. doi:10.1016/j.bbrc.2018.08.079  
15.   Kikuchi Haruhisa, Kawai Kosuke, Nakashiro Yota, et al. Construction of a Meroterpenoid‐Like Compounds Library Based on Diversity‐Enhanced Extracts. Chemistry – A European Journal. 2018; 25 (4): chem.201805417. doi:10.1002/chem.201805417  
16.   Watanabe Masahiro, Hashimoto Koichi, Abe Yusaku, et al. A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo. PLOS ONE. 2016; 11 (9): e0162823. doi:10.1371/journal.pone.0162823  
17.   Salie Zhe Li, Kirby Karen A., Michailidis Eleftherios, et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA). Proceedings of the National Academy of Sciences. 2016; 113 (33): 9274-9279. doi:10.1073/pnas.1605223113  
18.   Miyamoto Fusako, Kawaji Kumi, Oishi Shinya, et al. Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method. Antiviral Chemistry and Chemotherapy. 2015; 24 (2): 77-82. doi:10.1177/2040206615614164  
19.   Asai Teigo, Tsukada Kento, Ise Satomi, et al. Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides. Nature Chemistry. 2015; 7 (9): 737-743. doi:10.1038/nchem.2308  
20.   Hachiya Atsuko, Reeve Aaron B, Marchand Bruno, et al. Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy. 2013; 57 (9): 4554-4558. doi:10.1128/AAC.00283-13  
21.   Shimane Kazuki, Kawaji Kumi, Miyamoto Fusako, et al. HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. Antimicrobial Agents and Chemotherapy. 2013; 57 (8): 4035-4038. doi:10.1128/AAC.00237-13  
22.   Maeda Kenji, Desai Darshan V, Aoki Manabu, et al. Delayed emergence of HIV-1 variants resistant to 4’-ethynyl-2-fluoro-2’-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antiviral Therapy. 2013; 19 (2): 179-189. doi:10.3851/IMP2697